A number of patient advocates, including the Post-Finasteride Syndrome Foundation (PFSF), had petitioned the FDA to remove the anti-baldness drug Propecia (finasteride) from the market.  The FDA recently announced that the drug would remain on the market but agreed to revise the label for finasteride to include a notice about reports of suicidal behavior.  Merck…